Header Logo

Connection

Johnny Mahlangu to Young Adult

Back to Details
This is a "connection" page, showing publications Johnny Mahlangu has written about Young Adult.
Johnny Mahlangu
Connection Strength
1,862
Young Adult
  1. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
    View in: PubMed
    Score: 0,140
  2. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601.
    View in: PubMed
    Score: 0,105
  3. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019 May; 25(3):382-391.
    View in: PubMed
    Score: 0,099
  4. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
    View in: PubMed
    Score: 0,098
  5. Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. J Clin Apher. 2019 Feb; 34(1):44-50.
    View in: PubMed
    Score: 0,096
  6. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia. 2018 Nov; 24(6):921-929.
    View in: PubMed
    Score: 0,095
  7. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
    View in: PubMed
    Score: 0,095
  8. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia. 2017 Jan; 23(1):33-41.
    View in: PubMed
    Score: 0,083
  9. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 2016 Nov; 22(6):873-879.
    View in: PubMed
    Score: 0,082
  10. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan; 23(1):67-76.
    View in: PubMed
    Score: 0,082
  11. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 08 04; 128(5):630-7.
    View in: PubMed
    Score: 0,081
  12. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8.
    View in: PubMed
    Score: 0,080
  13. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16; 123(3):317-25.
    View in: PubMed
    Score: 0,068
  14. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012 May; 10(5):773-80.
    View in: PubMed
    Score: 0,061
  15. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. 2025 Jan; 31(1):78-86.
    View in: PubMed
    Score: 0,037
  16. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
    View in: PubMed
    Score: 0,032
  17. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood. 2022 04 28; 139(17):2642-2652.
    View in: PubMed
    Score: 0,030
  18. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
    View in: PubMed
    Score: 0,028
  19. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021 May; 27(3):398-407.
    View in: PubMed
    Score: 0,028
  20. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia. 2020 Nov; 26(6):e262-e271.
    View in: PubMed
    Score: 0,027
  21. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.
    View in: PubMed
    Score: 0,026
  22. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
    View in: PubMed
    Score: 0,024
  23. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. Haemophilia. 2018 Nov; 24(6):911-920.
    View in: PubMed
    Score: 0,024
  24. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018 Jan; 24(1):77-84.
    View in: PubMed
    Score: 0,022
  25. Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. Haemophilia. 2017 11; 23(6):e536-e538.
    View in: PubMed
    Score: 0,022
  26. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
    View in: PubMed
    Score: 0,022
  27. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 02 28; 117(3):508-518.
    View in: PubMed
    Score: 0,021
  28. Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia. 2016 Nov; 22(6):912-918.
    View in: PubMed
    Score: 0,021
  29. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872.
    View in: PubMed
    Score: 0,020
  30. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia. 2016 Jul; 22(4):e259-66.
    View in: PubMed
    Score: 0,020
  31. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0,020
  32. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016 May; 141:69-76.
    View in: PubMed
    Score: 0,020
  33. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015 May; 13(5):743-54.
    View in: PubMed
    Score: 0,019
  34. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800.
    View in: PubMed
    Score: 0,018
  35. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6.
    View in: PubMed
    Score: 0,018
  36. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015 Jan; 168(1):124-34.
    View in: PubMed
    Score: 0,018
  37. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014 Aug; 12(8):1244-53.
    View in: PubMed
    Score: 0,018
  38. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014 Sep; 20(5):687-92.
    View in: PubMed
    Score: 0,018
  39. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12; 369(24):2313-23.
    View in: PubMed
    Score: 0,017
  40. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan; 10(1):81-9.
    View in: PubMed
    Score: 0,015
  41. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol. 2008; 153(11):2049-58.
    View in: PubMed
    Score: 0,012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.